Skip to main content
Premium Trial:

Request an Annual Quote

Deloitte Joins TranSMART Membership Program


Deloitte said this week that it is now a gold-level sponsor of the TranSMART Foundation and that as part of its sponsorship, Brett Davis, a principal with Deloitte Consulting and general manager of Deloitte Health Informatics, will join the foundation's board of directors.

The TranSMART Foundation launched its membership program last October to provide an ecosystem for partners that are developing, delivering, hosting, supporting and using its platform for translational research, and a sustainable way to achieve is objectives. The program offers three levels of sponsorship that confer a variety of benefits on partners.

The TranSMART open-source knowledge-management platform helps life-science and health-care organizations integrate phenotypic clinical data and molecular information to develop and refine hypotheses in their translational research and personalized medicine projects.

"Recombinant by Deloitte is one of the original developers of the TranSMART platform, and I am very pleased to see their continued involvement in the community," Keith Elliston, Ph.D., CEO of the tranSMART Foundation, said in a statement. Dan Housman, Deloitte Consulting's director and chief technology officer of Recombinant by Deloitte, added that his firm is "proud to have been involved in the original tranSMART platform" and remains committed to investing in its development.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.